Tweet
J Virol. 2011 Nov 30. [Epub ahead of print]
Seasonal H1N1 infection induces cross protective pandemic H1N1 immunity through a CD8 independent, B cell dependent mechanism.
Fang Y, Banner D, Kelvin AA, Huang SS, Paige CJ, Corfe SA, Kane KP, Bleackley RC, Rowe T, Leon AJ, Kelvin DJ.
Source
Division of Immunology, International Institute of Infection and Immunity, Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong, P.R. China, 515041.
Abstract
During the 2009 pandemic (pdmH1N1) outbreak it was found that most individuals lacked antibodies against the new pdmH1N1, and only aged people showed anti-hemagglutinin (HA) antibodies that were cross-reactive with the new strains. Different studies have demonstrated that prior contact with the virus can confer protection against strains with some degree of dissimilarity, however, this has not been sufficiently explored within the context of a pdmH1N1 infection. In this study, we have found that a first infection with A/Brisbane/59/2007 confers heterologous protection in ferrets and mice against a subsequent pdmH1N1 2009 (A/Mexico/4108/2009) infection through a cross-reactive but non-neutralizing antibody mechanism. Heterologous immunity is abrogated in B cell-deficient mice but maintained in CD8 (-/-) and perforin-1(-/-) mice. We have identified cross-reactive antibodies from A/Brisbane/59/2007 sera that recognize non-HA epitopes in pdmH1N1 2009. Passive serum transfer showed that cross-reactive sH1N1-induced antibodies conferred protection in na?ve recipient mice during pdmH1N1 challenge. The presence or absence of anti-HA antibodies, therefore, is not the sole indicator of the effectiveness of protective cross-reactive antibody immunity. Measurement of additional antibody repertoires targeting the non-HA antigens of influenza virus need be taken into consideration in assessing protection and immunization strategies. We propose that pre-existing cross protective non-HA antibody immunity may have had an overall protective effect during the 2009 pdmH1N1, thereby reducing disease severity in human infections.
PMID:
22130540
[PubMed - as supplied by publisher]
Seasonal H1N1 infection induces cross protective pandemic H1N1 immunity through a CD8 independent, B cell dependent mechanism.
Fang Y, Banner D, Kelvin AA, Huang SS, Paige CJ, Corfe SA, Kane KP, Bleackley RC, Rowe T, Leon AJ, Kelvin DJ.
Source
Division of Immunology, International Institute of Infection and Immunity, Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong, P.R. China, 515041.
Abstract
During the 2009 pandemic (pdmH1N1) outbreak it was found that most individuals lacked antibodies against the new pdmH1N1, and only aged people showed anti-hemagglutinin (HA) antibodies that were cross-reactive with the new strains. Different studies have demonstrated that prior contact with the virus can confer protection against strains with some degree of dissimilarity, however, this has not been sufficiently explored within the context of a pdmH1N1 infection. In this study, we have found that a first infection with A/Brisbane/59/2007 confers heterologous protection in ferrets and mice against a subsequent pdmH1N1 2009 (A/Mexico/4108/2009) infection through a cross-reactive but non-neutralizing antibody mechanism. Heterologous immunity is abrogated in B cell-deficient mice but maintained in CD8 (-/-) and perforin-1(-/-) mice. We have identified cross-reactive antibodies from A/Brisbane/59/2007 sera that recognize non-HA epitopes in pdmH1N1 2009. Passive serum transfer showed that cross-reactive sH1N1-induced antibodies conferred protection in na?ve recipient mice during pdmH1N1 challenge. The presence or absence of anti-HA antibodies, therefore, is not the sole indicator of the effectiveness of protective cross-reactive antibody immunity. Measurement of additional antibody repertoires targeting the non-HA antigens of influenza virus need be taken into consideration in assessing protection and immunization strategies. We propose that pre-existing cross protective non-HA antibody immunity may have had an overall protective effect during the 2009 pdmH1N1, thereby reducing disease severity in human infections.
PMID:
22130540
[PubMed - as supplied by publisher]
